EMA建议Kisunla在初步拒绝后,在欧盟批准之前,接受早期老年痴呆症的治疗。 The EMA recommends Kisunla for early Alzheimer's, after initial rejection, pending EU approval.

欧洲医药局推荐Eli Lilly的阿尔茨海默氏症药物Kisunla(donanemab), The European Medicines Agency (EMA) has recommended Eli Lilly's Alzheimer's drug, Kisunla (donanemab), for adults with early-stage Alzheimer's disease and confirmed amyloid pathology. 在美国、日本、中国和英国已经批准的药物, 减缓了疾病的蔓延, 但有大脑膨胀和出血的风险。 The drug, already approved in the US, Japan, China, and the UK, slows disease progression but carries risks of brain swelling and bleeding. EMA的建议是在初步拒绝之后提出的,现在欧洲联盟委员会将决定其预期在几个月内批准。 The EMA's recommendation comes after initial rejection, and now the European Commission will decide on its approval, expected within months.